TRPV1 nociceptors in oral carcinogenesis and pain
TRPV1 伤害感受器在口腔癌发生和疼痛中的作用
基本信息
- 批准号:10600862
- 负责人:
- 金额:$ 60.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-01 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:Afferent NeuronsAgonistAttentionAttenuatedBehaviorBehavioralCalcitonin Gene-Related PeptideCalcitonin-Gene Related Peptide ReceptorCancer PatientCapsaicinCell LineCellsChemicalsClinical TrialsDataDisseminated Malignant NeoplasmEnrollmentEpithelial CellsFDA approvedFoundationsGangliaGenesGoalsGrowthHead and Neck Squamous Cell CarcinomaHyperalgesiaIncidenceInvadedMalignant NeoplasmsMeasurableMeasuresMediatorMicroRNAsMigraineModelingMusNeoplasm MetastasisNerveNeuronsNeuropeptidesNociceptionNociceptive StimulusNociceptorsNodalNonmetastaticOpioidPainPain MeasurementPainlessPatientsPeptide Signal SequencesPhenotypeProliferatingProteinsReportingResearchRodent ModelSamplingSensorySignal TransductionSpinal GangliaStainsStimulusStromal CellsStructure of trigeminal ganglionTRPV channelTRPV1 geneTestingTissuesTrigeminal Systemafferent nerveangiogenesisattenuationcancer cellcancer paincancer therapycarcinogenesischronic paincohortdensityexperienceextracellular vesiclesimmunoreactivityimprovedinnovationmalignant mouth neoplasmmechanical allodyniamembermouse modelnerve supplyneuroregulationnovel strategiesoral carcinogenesisoral painoverexpressionperineuralpreventprospectiveresponsespinal nerve posterior roottargeted treatmenttumor microenvironment
项目摘要
Project Summary
Oral cancer pain is more severe than all other cancers. Patients with metastatic oral cancer experience the
greatest pain. Oral cancers activate neurons and produce pain; however, the effect of nociceptors on oral
cancer is largely unknown. The mechanisms of reciprocal interaction between oral cancer and neurons, and
how the interactions promote cancer and pain, are not known. The long-term goal is to improve management
of oral cancer patients and obviate opioids by identifying components of the cancer microenvironment that are
viable targets to treat cancer and oral cancer pain. The overall objectives for this application are to (i) elucidate
the phenotype and distribution of transient receptor potential channel, vanilloid subfamily member (TRPV1) +
neurons innervating painful and metastatic oral cancers, (ii) measure sensitization and activation of TRPV1+
neurons by mediators secreted by oral cancer, and (iii) determine the contribution of TRPV1+ neurons to oral
carcinogenesis. The central hypothesis is that oral cancers release mediators, including mediators carried in
extracellular vesicles (EVs) that sensitize and activate nociceptors inducing oral cancer pain. The cancer-
primed nociceptors, in turn, promote cancer. The rationale for the project is that identification of components of
the cancer-nerve interaction provides the opportunity to develop approaches to treat oral cancer and oral
cancer pain, thereby reducing use of opioids. The central hypothesis will be tested by pursuing three specific
aims: 1) Determine the type and density of innervation in oral cancers in relation to pain and metastasis; 2)
Investigate sensitization of trigeminal (TG) neurons by cancer pain mediators; and, 3) Investigate cancer
promotion by cancer activated and sensitized TRPV1+ neurons and evaluate the potential to stop cancer and
alleviate cancer pain by antagonizing signaling via the sensory neuropeptide, calcitonin gene related peptide
(CGRP). Under the first aim, neuronal innervation of the cancer will be evaluated in a retrospective patient
cohort with known pain and nodal status, and testing for capsaicin (TRPV1 agonist) sensitivity and
measurement of pain will be performed in prospectively enrolled oral cancer patients. For the second aim, a
gene associated with pain and metastasis and miRNAs from EVs will be investigated as pain mediators. For
the third aim a mouse oral carcinogenesis model will be used to investigate the impact of TRPV1 abundance
on cancer incidence and phenotype, the impact of CGRP signaling on cancer promotion, and the potential for
CGRP/CGRP receptor therapies for treating and preventing oral cancer and oral cancer pain. The research
proposed is innovative because it is based on two new findings regarding oral cancer pain: (1) newly identified
putative cancer pain mediators overexpressed in metastatic cancers from patients reporting high levels of pain,
and (2) involvement of EVs in cancer induced nociceptive behavior. The proposed research is significant
because these studies will lay the foundation for clinical trials to assess CGRP and CGRP receptor targeted
therapies, which are FDA-approved for migraine, to treat cancer and attenuate cancer pain.
项目摘要
口腔癌疼痛比其他所有癌症都严重。转移性口腔癌患者经历
最大的痛苦口腔癌激活神经元并产生疼痛;然而,伤害性感受器对口腔癌的影响可能与疼痛有关。
癌症在很大程度上是未知的。口腔癌和神经元之间相互作用的机制,
这种相互作用如何促进癌症和疼痛尚不清楚。长期目标是改善管理
口腔癌患者和阿片类药物通过识别癌症微环境的成分,
治疗癌症和口腔癌疼痛的可行靶点。本申请的总体目标是(i)阐明
瞬时受体电位通道(TRPV 1)表型和分布
神经支配疼痛和转移性口腔癌的神经元,(ii)测量TRPV 1+的致敏和活化
通过口腔癌分泌的介质来确定TRPV 1+神经元对口腔癌的作用,以及(iii)确定TRPV 1+神经元对口腔癌的作用。
致癌作用中心假设是口腔癌释放介质,包括介质中携带的介质,
细胞外囊泡(EV),其敏化并激活诱发口腔癌疼痛的伤害感受器。癌症-
引发的伤害感受器反过来又促进癌症。该项目的基本原理是,
癌症-神经相互作用提供了开发治疗口腔癌和口腔癌的方法的机会。
癌症疼痛,从而减少阿片类药物的使用。中心假设将通过追求三个具体的测试
目的:1)确定口腔癌神经支配的类型和密度与疼痛和转移的关系; 2)
研究三叉神经(TG)神经元对癌痛介质的敏感性; 3)研究癌症
癌症的促进激活和致敏TRPV 1+神经元,并评估阻止癌症的潜力,
通过拮抗感觉神经肽、降钙素基因相关肽的信号传导来减轻癌症疼痛
(CGRP)。在第一个目标下,将在回顾性患者中评估癌症的神经支配
已知疼痛和淋巴结状态的队列,并测试辣椒素(TRPV 1激动剂)敏感性,
将在前瞻性入选的口腔癌患者中进行疼痛测量。对于第二个目标,A
与疼痛和转移相关的基因和来自EV的miRNA将作为疼痛介质进行研究。为
第三个目的是使用小鼠口腔癌发生模型来研究TRPV 1丰度的影响。
对癌症发病率和表型的影响,CGRP信号传导对癌症促进的影响,以及
用于治疗和预防口腔癌和口腔癌疼痛的CGRP/CGRP受体疗法。研究
建议是创新的,因为它是基于两个新的发现,关于口腔癌疼痛:(1)新发现的
在来自报告高水平疼痛的患者的转移性癌症中过表达的推定的癌症疼痛介质,
和(2)EV参与癌症诱导的伤害性行为。所提出的研究是有意义的
因为这些研究将为评估CGRP和CGRP受体靶向的临床试验奠定基础,
FDA批准用于治疗偏头痛的治疗方法,用于治疗癌症和减轻癌症疼痛。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Donna G Albertson其他文献
Chromosome aberrations in solid tumors
实体瘤中的染色体畸变
- DOI:
10.1038/ng1215 - 发表时间:
2003-07-30 - 期刊:
- 影响因子:29.000
- 作者:
Donna G Albertson;Colin Collins;Frank McCormick;Joe W Gray - 通讯作者:
Joe W Gray
Conflicting evidence on the frequency of ESR1 amplification in breast cancer
关于乳腺癌中 ESR1 扩增频率的相互矛盾的证据
- DOI:
10.1038/ng0708-821 - 发表时间:
2008-07-01 - 期刊:
- 影响因子:29.000
- 作者:
Donna G Albertson - 通讯作者:
Donna G Albertson
Donna G Albertson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Donna G Albertson', 18)}}的其他基金
TRPV1 nociceptors in oral carcinogenesis and pain
TRPV1 伤害感受器在口腔癌发生和疼痛中的作用
- 批准号:
10173219 - 财政年份:2021
- 资助金额:
$ 60.57万 - 项目类别:
TRPV1 nociceptors in oral carcinogenesis and pain
TRPV1 伤害感受器在口腔癌发生和疼痛中的作用
- 批准号:
10358603 - 财政年份:2021
- 资助金额:
$ 60.57万 - 项目类别:
Artemin overexpression in oral cancer pain and carcinogenesis
Artemin 过度表达在口腔癌疼痛和癌变中的作用
- 批准号:
10475175 - 财政年份:2019
- 资助金额:
$ 60.57万 - 项目类别:
Artemin overexpression in oral cancer pain and carcinogenesis
Artemin 过度表达在口腔癌疼痛和癌变中的作用
- 批准号:
10242843 - 财政年份:2019
- 资助金额:
$ 60.57万 - 项目类别:
Artemin overexpression in oral cancer pain and carcinogenesis
Artemin 过度表达在口腔癌疼痛和癌变中的作用
- 批准号:
10700882 - 财政年份:2019
- 资助金额:
$ 60.57万 - 项目类别:
FISH assay identifying oral cancer patients at low risk of lymph node metastasis
FISH 检测可识别淋巴结转移风险较低的口腔癌患者
- 批准号:
8719677 - 财政年份:2012
- 资助金额:
$ 60.57万 - 项目类别:
FISH assay identifying oral cancer patients at low risk of lymph node metastasis
FISH 检测可识别淋巴结转移风险较低的口腔癌患者
- 批准号:
8442841 - 财政年份:2012
- 资助金额:
$ 60.57万 - 项目类别:
FISH assay identifying oral cancer patients at low risk of lymph node metastasis
FISH 检测可识别淋巴结转移风险较低的口腔癌患者
- 批准号:
8257685 - 财政年份:2012
- 资助金额:
$ 60.57万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 60.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 60.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 60.57万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 60.57万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 60.57万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 60.57万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 60.57万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 60.57万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 60.57万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 60.57万 - 项目类别: